NPI: 1336155738 · LINCOLN, NE 68510 · Ambulatory Surgical Clinic/Center · NPI assigned 07/31/2006
Authorized official KUIPER, EVERT controls 20+ related entities in our dataset. Read more
| Authorized Official | KUIPER, EVERT (CEO - CHI HEALTH) |
| NPI Enumeration Date | 07/31/2006 |
Other providers sharing the same authorized official: KUIPER, EVERT
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 47,276 | $1.82M |
| 2019 | 46,113 | $1.84M |
| 2020 | 52,324 | $1.90M |
| 2021 | 97,592 | $2.70M |
| 2022 | 102,622 | $3.19M |
| 2023 | 53,721 | $2.11M |
| 2024 | 24,483 | $1.38M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 24,444 | 22,632 | $3.59M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 18,666 | 16,390 | $2.63M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4,105 | 2,947 | $909K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2,305 | 2,033 | $763K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4,685 | 4,039 | $724K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5,465 | 5,078 | $659K |
| 70450 | Computed tomography, head or brain; without contrast material | 2,145 | 1,940 | $488K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3,250 | 2,177 | $436K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3,460 | 3,295 | $295K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2,575 | 1,746 | $259K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 794 | 736 | $243K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2,946 | 2,841 | $239K |
| 59050 | 1,069 | 776 | $234K | |
| G0378 | Hospital observation service, per hour | 1,921 | 1,476 | $193K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 956 | 470 | $177K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2,259 | 1,581 | $172K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 10,756 | 8,845 | $113K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 552 | 524 | $101K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1,014 | 869 | $100K |
| 80053 | Comprehensive metabolic panel | 16,605 | 14,566 | $93K |
| 71046 | Radiologic examination, chest; 2 views | 1,925 | 1,847 | $92K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 124 | 109 | $86K |
| 96375 | Therapeutic injection; each additional sequential IV push | 6,684 | 5,144 | $86K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 442 | 428 | $83K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 658 | 601 | $80K |
| J7030 | Infusion, normal saline solution , 1000 cc | 9,598 | 7,488 | $80K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 970 | 697 | $80K |
| 84443 | Thyroid stimulating hormone (TSH) | 6,675 | 6,437 | $75K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 311 | 249 | $73K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 7,335 | 6,114 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 23,716 | 19,953 | $70K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2,328 | 2,143 | $69K |
| J3490 | Unclassified drugs | 28,870 | 12,301 | $67K |
| 80050 | General health panel | 6,714 | 5,924 | $59K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1,826 | 1,761 | $58K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2,338 | 2,251 | $52K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 383 | 377 | $48K |
| 84439 | 3,278 | 3,175 | $44K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 9,774 | 8,044 | $42K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 320 | 300 | $40K |
| 71045 | Radiologic examination, chest; single view | 5,416 | 4,671 | $38K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4,726 | 3,293 | $35K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 622 | 610 | $34K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 5,631 | 5,095 | $34K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3,785 | 3,625 | $33K |
| 16020 | 473 | 345 | $32K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,704 | 1,251 | $31K |
| 96376 | 2,461 | 1,377 | $30K | |
| 80061 | Lipid panel | 5,181 | 5,007 | $29K |
| 93971 | 181 | 171 | $26K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 7,580 | 5,929 | $25K |
| 36415 | Collection of venous blood by venipuncture | 12,066 | 9,301 | $25K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 582 | 547 | $23K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 4,353 | 2,948 | $23K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 634 | 542 | $23K |
| 85027 | 4,247 | 3,720 | $21K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 92 | 82 | $21K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1,039 | 1,028 | $21K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1,019 | 956 | $21K |
| J7050 | Infusion, normal saline solution, 250 cc | 1,992 | 1,007 | $19K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 42 | 39 | $17K |
| 86140 | 2,967 | 2,611 | $17K | |
| 74018 | 709 | 645 | $16K | |
| 87081 | 2,290 | 2,229 | $16K | |
| 76830 | Ultrasound, transvaginal | 277 | 266 | $15K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 4,677 | 4,051 | $15K |
| G0422 | Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session | 238 | 36 | $14K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 2,850 | 2,037 | $14K |
| 84484 | 6,155 | 4,171 | $14K | |
| 97116 | 540 | 191 | $13K | |
| 84702 | 1,154 | 921 | $12K | |
| 87480 | 1,593 | 1,462 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1,011 | 739 | $11K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 47 | 45 | $11K |
| 84703 | 3,747 | 3,414 | $11K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1,310 | 1,276 | $11K |
| 81001 | 9,979 | 8,862 | $10K | |
| 97165 | 368 | 293 | $10K | |
| 84145 | 531 | 457 | $10K | |
| 83690 | 5,707 | 4,879 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 3,561 | 2,497 | $10K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 13,845 | 5,866 | $9K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1,003 | 903 | $9K |
| 83880 | 980 | 818 | $9K | |
| 82607 | 668 | 634 | $9K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 25 | 24 | $9K |
| 82728 | 744 | 708 | $8K | |
| 87660 | 1,593 | 1,462 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 1,702 | 1,130 | $7K |
| 73610 | 257 | 241 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 112 | 98 | $7K |
| 87077 | 1,468 | 1,361 | $7K | |
| 59025 | Fetal non-stress test | 29 | 26 | $7K |
| 81514 | 66 | 61 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 2,490 | 2,084 | $7K |
| 81003 | 4,216 | 3,868 | $7K | |
| 87510 | 1,593 | 1,462 | $7K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 836 | 706 | $6K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 1,406 | 1,147 | $6K |
| 86803 | 568 | 547 | $6K | |
| 83735 | 2,137 | 1,486 | $6K | |
| 85652 | 1,625 | 1,511 | $6K | |
| 82962 | 4,893 | 1,751 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 326 | 286 | $6K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 115 | 114 | $6K |
| 86850 | 501 | 406 | $5K | |
| 76801 | 145 | 124 | $5K | |
| 87186 | 1,389 | 1,297 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 114 | 113 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 114 | 113 | $4K |
| 76536 | 27 | 25 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 30 | 12 | $4K |
| 11045 | 22 | 12 | $4K | |
| 73630 | 131 | 128 | $4K | |
| 80081 | 377 | 342 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 41 | 41 | $4K |
| 12001 | 12 | 12 | $4K | |
| 87040 | 873 | 668 | $4K | |
| J2704 | Injection, propofol, 10 mg | 2,638 | 2,070 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 1,138 | 942 | $4K |
| 86900 | 635 | 524 | $4K | |
| 86480 | 99 | 90 | $4K | |
| 97535 | Self-care/home management training, each 15 minutes | 305 | 130 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 688 | 657 | $4K |
| 97161 | 336 | 273 | $4K | |
| 85610 | 2,027 | 1,652 | $4K | |
| 83540 | 712 | 677 | $4K | |
| 83605 | 1,262 | 1,019 | $4K | |
| 70486 | 41 | 40 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 971 | 715 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 1,863 | 1,557 | $3K |
| 85379 | 1,368 | 1,205 | $3K | |
| 87070 | 627 | 501 | $3K | |
| 76642 | 17 | 13 | $3K | |
| A9270 | Non-covered item or service | 6,716 | 1,220 | $3K |
| A4217 | Sterile water/saline, 500 ml | 163 | 134 | $2K |
| 82950 | 421 | 413 | $2K | |
| 80076 | 437 | 400 | $2K | |
| 83550 | 371 | 346 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 49 | 44 | $2K |
| 87807 | 121 | 119 | $2K | |
| 81025 | 1,503 | 1,378 | $2K | |
| 72100 | 44 | 40 | $2K | |
| 87210 | 844 | 787 | $2K | |
| 73110 | 81 | 69 | $2K | |
| 85730 | 628 | 549 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 96 | 84 | $1K |
| 82043 | 493 | 484 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 784 | 519 | $1K |
| 84481 | 163 | 160 | $1K | |
| 94760 | 1,163 | 724 | $1K | |
| 87420 | 159 | 159 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 151 | 145 | $1K |
| 87147 | 399 | 372 | $1K | |
| 86780 | 139 | 127 | $1K | |
| 86901 | 784 | 652 | $1K | |
| 84153 | 124 | 122 | $1K | |
| A4649 | Surgical supply; miscellaneous | 392 | 350 | $1K |
| 73030 | 212 | 192 | $1K | |
| 80306 | 66 | 64 | $1K | |
| 83516 | 83 | 76 | $972.12 | |
| 86038 | 98 | 94 | $929.99 | |
| 87205 | 593 | 464 | $892.95 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 125 | 63 | $887.37 |
| 84112 | 28 | 26 | $834.75 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 281 | 190 | $831.97 |
| 90715 | 31 | 31 | $812.77 | |
| 84100 | 554 | 367 | $806.38 | |
| 96367 | 60 | 41 | $787.58 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,915 | 1,635 | $728.66 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 128 | 37 | $702.30 |
| 94761 | 461 | 210 | $652.40 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 55 | 52 | $652.21 |
| 51701 | 27 | 27 | $646.07 | |
| 99152 | 13 | 12 | $611.55 | |
| 71250 | 15 | 13 | $569.14 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 82 | 81 | $463.32 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 274 | 260 | $419.41 |
| 73130 | 109 | 98 | $360.37 | |
| 84403 | 27 | 27 | $342.76 | |
| 83001 | 27 | 25 | $256.22 | |
| 86376 | 28 | 26 | $254.27 | |
| 73560 | 186 | 150 | $244.63 | |
| 82570 | 94 | 83 | $230.31 | |
| 36600 | 16 | 16 | $230.11 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 388 | 355 | $224.30 |
| 82670 | 13 | 13 | $205.43 | |
| 94762 | 17 | 13 | $174.34 | |
| 86431 | 27 | 27 | $172.41 | |
| J2060 | Injection, lorazepam, 2 mg | 443 | 307 | $164.25 |
| 84270 | 12 | 12 | $153.47 | |
| 82746 | 14 | 14 | $147.78 | |
| 88342 | 16 | 14 | $122.41 | |
| 84146 | 12 | 12 | $122.32 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 15 | 14 | $110.00 |
| 87075 | 38 | 24 | $108.93 | |
| 84156 | 64 | 54 | $85.34 | |
| 73502 | 39 | 37 | $62.97 | |
| 88304 | 17 | 15 | $47.73 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 33 | 24 | $47.56 |
| J1815 | Injection, insulin, per 5 units | 32 | 12 | $46.04 |
| J3480 | Injection, potassium chloride, per 2 meq | 48 | 27 | $45.11 |
| 82550 | 18 | 15 | $32.07 | |
| 82270 | 14 | 12 | $24.92 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 222 | 181 | $22.89 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 661 | 210 | $21.68 |
| 85018 | 17 | 13 | $17.23 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 21 | 19 | $16.37 |
| 82803 | 17 | 12 | $14.71 | |
| 82077 | 691 | 579 | $14.57 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 12 | 12 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 19 | 15 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 18 | 12 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 105 | 81 | $0.00 |
| 80179 | 15 | 13 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 12 | 12 | $0.00 |
| 85007 | 14 | 12 | $0.00 | |
| 80143 | 15 | 13 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 178 | 158 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 63 | 52 | $0.00 |